Bio/Pharma News

Sangamo BioSciences has agreed to acquire Ceregene, a privately held biotechnology company focused on developing adeno-associated virus (AAV) gene therapies.

Santaris Pharma and Shire have extended their partnership in the rare genetic disease space.

Understanding the supply-chain challenge and coupling high-efficiency chromatographic techniques with information-rich detectors are leading to improvements in the management of extractables and leachables in parenteral drugs.

A simple, rapid analytical method for the determination of palladium in pharmaceutical production samples will speed up development and optimization of reactions involving palladium catalysts.

Bristol-Myers Squibb Company and Samsung BioLogics announced the companies have entered into a 10-year agreement.

Wyeth Pharmaceuticals has agreed to pay $490.9 million to resolve its criminal and civil liability arising from the unlawful marketing of the prescription drug Rapamune for uses not approved as safe and effective by FDA.

Kemwell Biopharma announced that it has acquired Cirrus Pharmaceuticals Inc., a contract development services company based in Research Triangle Park, N.C.

A roundup of developments in global health and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.

Research will focus on cancer and viral disease targets not addressable using antibody-based technologies.

A roundup of developments in global health and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.

Highlights from the 66th World Health Assembly and the pharmaceutical industry?s role in addressing noncommunicable diseases, mental and neurological disorders, R&D for diseases of the developing world, counterfeit medicines, the global vaccine action plan, and neglected tropical diseases.

The agreement is worth up to $552 million, depending on meeting set milestones.

-

Unither Pharmaceuticals will acquire an UCB Rochester, NY pharmaceutical plant used to liquid pharmaceutical products.

The Global Vaccine Action plan maps out a strategy to increase access and R&D for vaccines.

Regeneron, a biopharmaceutical company based in New York, has announced plans to expand its corporate headquarters and laboratories in Westchester. This expansion will create more than 400 new highly skilled jobs and further cement Hudson Valley's reputation as an emerging epicenter for biopharmaceutical growth.

Company considers investment in insulin cartridge-filling and insulin API manufacturing capacity in the US.

Teva and Lonza have announced that their joint venture will continue to develop, manufacture and market affordable, efficacious and safe biosimilars.

Company issues voluntary recall after learning of complaints of an uncharacteristic odor coming from Levoxyl bottles.

Astellas and Ambrx have entered into a collaboration to discover and develop novel antibody drug conjugates (ADCs) for an undisclosed number of targets in oncology. ADCs enable targeted delivery of drugs to the target tissue.

The Access to Medicines Index shows that pharmaceutical companies are increasing drug development for the developing world and using more tiered pricing mechanisms to lower pricing.

A roundup of developments in corporate social responsibility (CSR) and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations

Draft guidance combines and supersedes previous guidance documents.

Merck's Januvia [sitagliptin] was named 2013 Brand of the Year by Pharmaceutical Executive magazine.

A roundup of developments in corporate social responsibility (CSR) and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.

A roundup of developments in corporate social responsibility (CSR) and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.

Endo Pharmaceuticals and GVK Biosciences (GVK BIO), a contract research organisation (CRO) based in India, have entered into an agreement to collaborate on the development of small molecules targeting an undisclosed protein. Using its discovery expertise, GVK BIO will deliver a clinical candidate and Endo will be responsible for the development and commercialisation of the product.

Ben Venue Laboratories announced that it has voluntarily entered into a consent decree with FDA over violations of cGMP.

GlaxoSmithKline has formed a joint venture with Indian vaccines company Biological E to research and develop a six-in-one combination pediatric vaccine to help protect children in India and other developing countries from certain infectious diseases.

AstraZeneca and Ceram Research, a materials development company based in the UK, have signed an agreement whereby Ceram will develop its inorganic-based controlled release technology in a feasibility study for delivering select AstraZeneca compounds.